Piramal Pharma Ltd (PPLPHARMA) is currently trading at 239.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Piramal Pharma Limited is a global pharmaceutical company operating across an integrated contract development and manufacturing organization, complex hospital generics, and Indian consumer healthcare, supported by 17 facilities and distribution in more than 100 countries. Its portfolio spans specialized CDMO services, hospital therapies, and over-the-counter consumer products. The company delivered unusually strong operating leverage in H1FY27: revenue increased 23%, while EBITDA rose 72% and margin expanded from 9.8% to 13.7%. This indicates that capacity utilization, execution discipline, and cost optimization are converting revenue growth into profitability faster than the underlying top-line expansion. CDMO is emerging as the principal growth engine, with H1 revenue growth of 28%, ADC services growth of 51%, on-patent commercial manufacturing growth of 39%, and differentiated offerings contributing 43% of CDMO revenue. The addition of 22 customers and growth in Phase III molecules point toward strengthening future commercial visibility. Piramal Pharma Limited combines strong market positions with a meaningful portfolio transition. CHG retains leadership in US Sevoflurane and Intrathecal Baclofen, while Consumer Healthcare is shifting toward owned Power Brands, premiumization, and e-commerce to reduce dependence on lower-margin distribution activity. The natural expiry of the Bayer distribution agreement in December 2026 is not expected to materially affect FY27 guidance. Bayer represented 5% of FY26 consolidated revenue but had a low 4.5% EBITDA margin, so its exit may modestly improve the consolidated margin profile if own-brand growth remains sustained.

Over the past 52 weeks, Piramal Pharma Ltd has traded between a low of ₹132.50 and a high of ₹239.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Piramal Pharma Ltd has a market capitalization of approximately 30,700.89. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Piramal Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -146.63 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 30,700.89 Cr, Piramal Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Piramal Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Piramal Pharma Ltd is -146.63. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Piramal Pharma reported Q1 FY27 revenue of ₹2,269.92 crore, up 17.39% year-on-year and down 17.51% quarter-on-quarter.

The disclosures state Piramal Pharma’s stake rises from 33.33% to approximately 74%, making Yapan Bio a subsidiary.

Piramal Pharma invested INR 101.77 crore in Yapan Bio, as disclosed in its Dec. 21, 2021 announcement.

The 6th AGM was held on July 30, 2026, and shareholders approved all ten resolutions, including NCD issuance via private placement and other governance items.